Expert Discusses Promise of Immunotherapy in TNBCAngelica Welch @awelchhhh
Published Online: Friday, Mar 17, 2017
The combination of immunotherapy and chemotherapy is showing promising response rates in certain patients with triple-negative breast cancer (TNBC), said ESO Umberto Veronesi Memorial Award Winner Giuseppe Curigliano, MD, PhD, who addressed genetic determinants of breast cancer immunogenicity in his award lecture at the 15th St. Gallen International Breast Cancer Conference.
– See more at: http://www.onclive.com/conference-coverage/st-gallen-2017/expert-discusses-promise-of-immunotherapy-in-tnbc#sthash.vMO84Khg.dpuf
Fighter Coming Through 